Is 688185.SS overvalued or undervalued?

688185.SS currently has a P/E ratio of 505.81. Relative to the sector average of 26.80, this suggests the stock may be overvalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy CanSino Biologics Inc. stock?

CanSino Biologics Inc. trades on SHH. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 688185.SS?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 688185.SS protect my money against local inflation?

Many investors in Latin America buy international stocks like 688185.SS to protect their purchasing power. Because 688185.SS is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 688185.SS shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 688185.SS a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 688185.SS diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks688185.SS

CanSino Biologics Inc.

¥98.46-¥1.10-1.10%

SHH / CNY

Market cap

¥18.0B

P/E

505.8

EPS (TTM)

¥0.02

Dividend yield

0.00%

Beta

1.22

1Y return

+25.75%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$677M2021

$150M2022

$50M2023

$116M2024

$132M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.20Low
Current ratio4.39
Cash ratio1.59
Net margin3.3%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

688185.SS505.8
Healthcare sector median26.8
S&P 50022.0

Trades about 1,787% above its sector, the market expects faster growth.

Ratios

PEG1.77
Price to book4.92
EPS (TTM)¥0.02
Payout ratio0%
FCF yield-1.01%

Range & risk

¥46.89¥108.00

Trading in the upper third of its 52-week band

Beta1.22

Profile

What CanSino Biologics Inc. actually does

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CEO

Xue Feng Yu

Employees

1,134

Headquarters

Tianjin, TI

Founded

2020-08-13

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 688185.SS and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

688185.SS has a beta of 1.22, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

CanSino Biologics Inc.